alopecia

Posts

Treatment of alopecia universalis

Five updates for Alopecia Areata Awareness Month

Five updates for Alopecia Areata Awareness Month

Alopecia areata affects up to 6.8 million people in the U.S. and carries a 2.1% lifetime risk, according to the National Alopecia Areata Foundation. The foundation has dubbed September “Alopecia Areata Awareness Month” to increase awareness, spread empowerment and raise funds for research into this polygenic autoimmune disease.

In honor of this awareness month, Healio Dermatology has compiled the following recent articles that explore treatment pathways and the latest research in alopecia areata.

JAK inhibitor promotes hair growth in both men, women with androgenetic alopecia

Inflammation plays a key role in male and female pattern hair loss, Neal Walker, DO, president and CEO of Aclaris Therapeutics, said in an interview with Healio Dermatology regarding results from a phase 2 open-label clinical trial in patients with androgenetic alopecia. Read more

Top-line results show efficacy of LED cap for androgenetic alopecia

Data from a randomized, double-blind, placebo-controlled trial demonstrated that Revian Red – an LED cap for the treatment of androgenic alopecia — may stop hair loss and subsequently grow new hair, according to a press release. Read more

Systemic therapy with JAK inhibitors may be future of alopecia areata treatment

There are no reliable, effective therapies for severe disease in alopecia areata; however, systemically administered Janus kinase inhibitors hold potential for the treatment of the condition, as well as vitiligo, according to a presenter at the AAD Summer Meeting. Read more

Hidradenitis suppurativa increases risk for alopecia

In a study investigating the relationship between hidradenitis suppurativa and alopecia areata in a U.S. sample, those with hidradenitis suppurativa had a significantly higher risk for alopecia of any type and also lichen planopilaris. Read more

Cyclosporin ‘moderately effective’ at inducing remission of alopecia areata

Adults with moderate to severe alopecia areata treated with cyclosporin had a greater reduction in Severity of Alopecia Tool score over time when compared with a placebo group in a randomized trial. Read more

Alopecia Areata Awareness Month

Source

Previous Posts

Treatment of alopecia universalis

Five updates for Alopecia Areata Awareness Month

Five updates for Alopecia Areata Awareness Month

Alopecia areata affects up to 6.8 million people in the U.S. and carries a 2.1% lifetime risk, according to the National Alopecia Areata Foundation. The foundation has dubbed September “Alopecia Areata Awareness Month” to increase awareness, spread empowerment and raise funds for research into this polygenic autoimmune disease.

In honor of this awareness month, Healio Dermatology has compiled the following recent articles that explore treatment pathways and the latest research in alopecia areata.

JAK inhibitor promotes hair growth in both men, women with androgenetic alopecia

Inflammation plays a key role in male and female pattern hair loss, Neal Walker, DO, president and CEO of Aclaris Therapeutics, said in an interview with Healio Dermatology regarding results from a phase 2 open-label clinical trial in patients with androgenetic alopecia. Read more

Top-line results show efficacy of LED cap for androgenetic alopecia

Data from a randomized, double-blind, placebo-controlled trial demonstrated that Revian Red – an LED cap for the treatment of androgenic alopecia — may stop hair loss and subsequently grow new hair, according to a press release. Read more

Systemic therapy with JAK inhibitors may be future of alopecia areata treatment

There are no reliable, effective therapies for severe disease in alopecia areata; however, systemically administered Janus kinase inhibitors hold potential for the treatment of the condition, as well as vitiligo, according to a presenter at the AAD Summer Meeting. Read more

Hidradenitis suppurativa increases risk for alopecia

In a study investigating the relationship between hidradenitis suppurativa and alopecia areata in a U.S. sample, those with hidradenitis suppurativa had a significantly higher risk for alopecia of any type and also lichen planopilaris. Read more

Cyclosporin ‘moderately effective’ at inducing remission of alopecia areata

Adults with moderate to severe alopecia areata treated with cyclosporin had a greater reduction in Severity of Alopecia Tool score over time when compared with a placebo group in a randomized trial. Read more

Alopecia Areata Awareness Month

Source

Previous Posts

Alopecia Treatment Market

Global Androgenic Alopecia Drug Market

Global Androgenic Alopecia Drug Market By Product Type (RK-023, Refagro) And By End-Users/Application (Clinic, Hospital) Global Market Share, Forecast Data, In-Depth Analysis, And Detailed Overview, and Forecast, 2013 – 2026

Global Androgenic Alopecia Drug Market is accounted for xx USD million in 2019 and is expected to reach xx USD million by 2026 growing at a CAGR of xx% during the forecast period. The report offers in-depth insights, revenue details, and other vital information regarding the global Androgenic Alopecia Drug market and the various trends, drivers, restraints, opportunities, and threats in the target market till 2026.

Androgenic Alopecia Drug Market report covers size, share and forecast (value and volume) by regions, top players, product types and applications, with historical data along with forecast from 2019 to 2026; The report covers an in depth description, competitive scenario, wide product portfolio of key vendors and business strategy adopted by competitors along with their SWOT analysis, revenue, sales and Porter’s Five Forces Analysis.

By geography, this market has been segregated into five regions with revenue and growth rate of Androgenic Alopecia Drug from 2013 to 2026,

• North America  (U.S., Canada, Mexico)
• Europe (U.K., France, Germany, Spain, Italy, Central & Eastern Europe, CIS)
• Asia Pacific (China, Japan, South Korea, ASEAN, India, Rest of Asia Pacific)
• Latin America (Brazil, Rest of L.A.)
• Middle East And Africa(Turkey, GCC, Rest of Middle East)

The major players operating into Androgenic Alopecia Drug Market include:

Histogen kick starts clinical trial for female hair lossAllergan, Inc.
Histogen, Inc.
R-Tech Ueno, Ltd.
Hygeia Therapeutics, Inc.
SWITCH Biotech LLC
Polichem S.A.
Kasiak Research Pvt. Ltd.

This report segments the Global Androgenic Alopecia Drug Market as follows:

Global Androgenic Alopecia Drug Market: Type Segment Analysis
RK-023
Refagro
RCH-01
SM-04554
HYG-440
Others

Global Androgenic Alopecia Drug Market: Application Segment Analysis
Clinic
Hospital
Home Use

There are 13 chapters to put on view for Androgenic Alopecia Drug Market:

Chapter 1: Market Overview, Drivers, Restraints and Opportunities, Segmentation overview
Chapter 2: Market competition by Manufacturers
Chapter 3: Production by Regions
Chapter 4: Consumption by Regions
Chapter 5: Production, By Types, Revenue and Market share by Types
Chapter 6: Consumption, By Applications, Market share (%) and Growth Rate by Applications
Chapter 7: Complete profiling and analysis of Manufacturers
Chapter 8: Manufacturing cost analysis, Raw materials analysis, Region-wise manufacturing expenses
Chapter 9: Industrial Chain, Sourcing Strategy and Downstream Buyers
Chapter 10: Marketing Strategy Analysis, Distributors/Traders
Chapter 11: Market Effect Factors Analysis
Chapter 12: Market Forecast
Chapter 13: Androgenic Alopecia Drug Research Findings and Conclusion, Appendix, methodology and data source

Data type include capacity, production, market share, price, revenue, cost, gross, gross margin, growth rate, consumption, import, export have been determined using secondary sources and verified primary sources. Industry chain, manufacturing process, cost structure, marketing channel are also analyzed in this report.

Industry Chain Analysis

Raw Material and Suppliers
Equipment and Suppliers
Manufacturing Process
Manufacturing Cost Structure
Manufacturing Plants Distribution Analysis

Available Customizations

We can also provide customized report as per company’s specific needs. We can also provide the customized separate regional or country-level reports, for the specific region as per client requirement.

Global Androgenic Alopecia Drug Market

Source

Previous Posts

Fast Shampoo

Hair Styling Products Market

Hair Styling Products Market: Global Industry Analysis 2013-2017

This report on the hair styling products market provides the forecast and analysis of the global hair styling products market. It provides analysis on the basis of historical data and forecast from 2017 to 2027 in terms of revenue (US$ Mn). The hair styling products report reveals the market dynamics in seven geographic segments along with market analysis for the current and future scenario. In addition, it includes drivers, restraints and recent trends of the hair styling products market.

The hair styling products market report also comprises opportunities for the manufacturers of hair styling products and highlights the value chain analysis in detail. The study demonstrates the market dynamics and trends across regions that are expected to influence the current status and future prospects of the hair styling products market.

The report studies the global hair styling product market period 2018–2027. The prime objective of this report is to offer quantitative and qualitative insights and the study key market trends pertaining to the global hair styling products market that gradually help transform businesses.

The hair styling products market numbers have been assessed by carefully scrutinizing the hair styling products spending of countries in all the seven key regions for the current year, as well as the historical performance of the market. Market size and forecast for each segment in the hair styling products market has been provided in the context of regional markets.

All the segmentation of the hair styling products market has been considered after appropriate secondary research and revalidation of the data obtained through interviews with key thought leaders and industry experts. The market has been forecast based on constant currency rates. The report includes the revenue generated from sales of hair styling products across all regional economies.

The report begins with an executive summary intended to provide a clear perspective about the hair styling products market to the reader. It is then followed by an overview of the hair styling products market and provides the definition of the market along with an analysis about the drivers, restraints, opportunities and key trends in the hairstyling products market. The sections that follow includes the analysis of the global hair styling products market by product type, source, end use, sales channel and a country-level analysis.

On the basis of product type, the global hair styling products market is segmented into hair gel, hair spray, styling creams & waxes, hair mousse and other types of hair styling products. The global hair styling products market is further segmented on the basis of end use. The potential end users are household, salon & spa and the fashion industry.

The global hair styling products market is again segmented on the basis of gender i.e. male, female and unisex. On the basis of sales channel, the global hair styling products market is segmented into wholesaler/distributor, supermarket/hypermarket, convenience store, specialty store and online store.

All the above sections evaluate the hair styling products market on the basis of various factors affecting the market, which cover the present scenario as well as the future prospects.

For market data analysis, the report considers 2017 as the base year, with market numbers estimated for 2018 and forecast made for 2018–2027. All the segmentation of the hair styling products market has been considered after appropriate secondary research and revalidation of the data obtained through interviews with key thought leaders in the industry. The hair styling products market has been forecast based on constant currency rates.

The next section of the hair styling products report highlights the market by region and provides the market outlook for 2018–2027. The study investigates the regional Year-on-Year (Y-o-Y) growth of the hair styling products market. Key regions assessed in this report include North America, Latin America, Europe, Asia Pacific Excluding Japan, Middle East & Africa and Japan. The report evaluates the present scenario and growth prospects of the regional market for 2018–2027.

The hair styling products market numbers have been assessed based on the sales and the weighted average pricing of hair styling products by nature and product type. The aggregate revenue is derived through the weighted average country pricing trends. The hair styling products market size and forecast for each segment have been provided in the context of countries. The hair styling products market has been analysed based on the expected demand and current spending scenario.

The prices considered for the calculation of revenue are the average country prices obtained through primary quotes from numerous regional manufacturers, suppliers and distributors of hair styling products. All the key product types have been considered on the basis of secondary sources, i.e. OECD, UN data and feedback from primary respondents. Country-wise demand patterns have been considered while estimating the consumption of hair styling products across various regions.

Hair styling products market numbers for all the regions by product type, base material, end use and distribution channel have been derived using the bottom-up approach, which is cumulative of each country’s demand.

The company-level hair styling products market share has been derived on the basis of the revenues reported by key manufacturers. The hair styling products market has been forecast based on constant currency rates.

Given the characteristics of the market, we have triangulated the outcome on the basis of three different types of analysis: based on supply side, demand side analysis for hair styling products and the impact of macro-economic factors on the hair styling products market.

In addition, it is imperative to note that, in a fluctuating global economy, we not only conduct market forecasts in terms of Compound Annual Growth Rate (CAGR), but also analyse the market based on key parameters, such as Y-o-Y growth rates, to understand the predictability of the hair styling products market and identify the right opportunities for players.

The market segments for the global hair styling products market have been analysed in terms of Basis Point Share (BPS) to understand the relative contributions of each segment to market growth. This detailed level of information is important for identifying various key trends in the hair styling products market.

Another key feature of this report is the analysis the market in terms of absolute dollar opportunity represented by the sales of hair styling products. Absolute dollar opportunity is critical for evaluating the scope of opportunity that a provider can look to achieve as well as to identify the lucrative segments.

he overall absolute dollar opportunity represented by the hair styling products market is mentioned in the report. To understand key growth segments in terms of growth and adoption for hair styling products in the global market, XploreMR has developed the market ‘Attractiveness Index.’ The resulting index is expected to help providers identify the real market opportunities.

A number of primary and secondary sources were referred during the course of the study. Some of the secondary sources include IMF, World Bank, Hoovers, Factiva, annual reports of companies and government associations & publications.

In the final section of the report on the hair styling products market, a ‘dashboard view’ of the companies has been provided to compare the current industrial scenario and their contribution in the overall hair styling products market.

Moreover, it is primarily designed to provide clients an objective and detailed comparative assessment of the key providers specific to a segment in the hair styling products market.

Report audiences can gain segment-specific manufacturer insights to identify and evaluate the key competitors in the hair styling products market. Detailed profiles of companies are also included in the report to evaluate their strategies, key product offerings and recent developments.

Some of the key players of the global hair styling products market are Procter & Gamble, L’Oreal, Unilever plc, Shiseido Company, Amorepacific Corporation, Flora Ltd., Kao Corporation, Henkel AG & Company, Godefroy Manufacturing Company, Swallowfield plc, Shu Uemura Art of Hair, Vogue International LLC, CURLS(R), LLC, Ouai haircare, Redken, Scental Pacific, Delta Laboratories Pty Ltd., Natrocare Laboratories, Mizani and Mielle Organics LLC.

Hair Styling Products Market: Global Industry Analysis 2013-2017

Source

Previous Posts

GKhair was Bright and Beautiful at Premiere Orlando 2019

GKhair was Bright and Beautiful at Premiere Orlando 2019

GKhair was Bright and Beautiful at Premiere Orlando 2019

Premiere Orlando was held from 2nd – 3rd June this year and GKhair participated in full swing, bringing the newest in technique and technology to stage.

With a resolve for imparting education, the brand has always been on the front line at similar events where artists from all over the world gather to learn and educate.

This year, many GKhair artists presented their skills on stage and attracted a large crowd of onlookers.

Multiple techniques like hair taming, styling, cuts and colors were displayed during the two days of exhibition at the event. Consequently, the GKhair stage was crowded throughout the event that lasted for two days.

The main focus at the GKhair stage was a new innovative technique of hair color – Bamboo Color – recently developed by Federico Longo from Italy. Bamboo Color has been inspired by the bamboo shoots to achieve customized yet natural end results. The technique embodies coloring and lightening hair at the same time.

Apart from that, several other educators also remained active at the stage, where they carried out live transformations sharing their knowledge and skills regarding coloring, styling, and hair taming.

GKhair’s brand new Flat Irons – One Control Titanium Flat Iron, D700 Titanium Flat Iron, and Easy Control Titanium Flat Iron – were also featured at the stage.
These irons have been receiving amazing feedback since they made it to the GKhair product line.

Besides, famous Venezuelan hair artist, Andrés Aragòn also visited the GKhair stage and took keen interest in the unique display of talent. It was very heartening for the GKhair team to see hair artists and partners coming in from different parts of the world to show their love and appreciation for the efforts of the brand to empower the hair industry.

Find more lively details about the event, here.

About GKhair

Operating in more than 75 countries, GKhair is a US-based haircare brand that has millions of clients across the world.

GKhair was Bright and Beautiful at Premiere Orlando 2019

 

Source

Previous Posts

Alopecia Treatment Market

Alopecia Treatment Market

Alopecia (Hair Loss)Treatment Market: Global Industry Analysis and Forecast 2016 – 2022

Alopecia is a term used to describe excessive hair damage under certain medical conditions or dietary issues. A sedentary lifestyle and unhealthy diets are leading to loss of hair among masses.

Furthermore, ageing and hormonal imbalance, increasing chronic disease like arthritis, cancer, hypertension, depression also lead to hair loss, especially among the middle-aged population. According to the American Hair Loss Association, androgenetic alopecia accounts for over 95% of hair loss in men.

Over 800 thousand patients are seeking some kind of treatment for hair loss worldwide. For the treatment of alopecia, U.S. FDA proved two drugs – Minoxidil, to treat hypertension and finasteride (Propecia) to treat benign prostate hyperplasia (BPH).  The American Hair Loss Association recommends the use of minoxidil in patients who have not responded to finasteride treatment.

The prevalence rate of alopecia is high among working age population. Treatment seeking rate for alopecia is more prevalent in developed regions as compared to that in developing regions, however, over the past few years, demand for alopecia treatment has increased dramatically in developing regions such as China and India owing to increase in healthcare expenditure and improved healthcare infrastructure facilities.

In China, 6 percent of females and 21 percent of males suffer from hormone-driven hair loss.

Changing lifestyle along with an increase in stress level among the working-class population is expected to boost the demand for treatment of hair loss globally. Furthermore, the rise in geriatrics population along with high demand for surgical hair transplant is expected to drive the alopecia treatment market.

Increasing consumer disposable incomes and health awareness, emphasis to look good and technological advancement in hair treatment medical devices are some other key drivers for this market. Since accessibility for scalp treatment is easily accessible and available, the demand for alopecia treatment has increased.

Though the market is expected to witness healthy growth during the forecast period, high cost of the medications and possible side effects/allergic reactions are acting as a key barrier for alopecia market.

Alopecia Treatment Market is broadly classified on the basis of the following segments –

Alopecia Treatment Market by Product:

  • Vitamins and Supplements
  • Shampoos and Conditioners
  • Others (Serums, gels, and oils)

Alopecia Treatment Market by Gender:

  • Men
  • Women
  • Children

Alopecia Treatment Market by End User:

  • Homecare Settings
  • Dermatology Clinics
  • Others (Salons)

The alopecia treatment market has grown substantially at a healthy CAGR due to changing lifestyle and greater emphasis on outward appearance to look good. With rapid technological advancement and innovation, alopecia treatment market is expected to grow globally. North America is the largest market for alopecia treatment while the Asia Pacific is expected to be the fastest growing market during the forecast period.

The alopecia treatment market is expected to register a significant CAGR during the forecast period. Depending on geographic regions, alopecia treatment is segmented into seven key regions: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America, followed by Europe, is expected to dominate the alopecia treatment market throughout the forecast period.

The Asia Pacific excluding Japan is poised to witness the fastest growth owing to outburst of the middle-aged population in the region. Also, the region is witnessing healthy growth in terms of GDP, which in turn is expected to propel growth at healthy digits. The Middle East & Africa and Latin America are expected to sluggish growth during the forecast period.

Some of the key market players for alopecia treatment market are Cipla, Viviscal, Dr. Reddy’s Laboratories Ltd., Regaine, Merck & Co., Inc, Ranbaxy Laboratories Ltd, Phyto – Alès Groupe, Kirkland Signature, Vitabiotics, Nanogen, Alpecin – Dr. Kurt Wolff GmbH & Co. KG, Rogaine – Johnson, and Johnson.

The report covers exhaustive analysis on:

  • Alopecia Treatment Market Segments
  • Alopecia Treatment Market Dynamics
  • Historical Actual Market Size, 2013 – 2015
  • Alopecia Treatment Market Size & Forecast 2016 to 2022
  • Alopecia Treatment Market Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Alopecia Treatment Market Drivers and Restraints

Regional analysis includes

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • The Middle East and Africa

Report Highlights:

  • Shifting Industry dynamics
  • In-depth market segmentation
  • Historical, current and projected industry size
  • Recent industry trends
  • Key Competition landscape
  • Strategies of key players and product offerings
  • Potential and niche segments/regions exhibiting promising growth
  • A neutral perspective towards market performance

Alopecia (Hair Loss)Treatment Market: Global Industry Analysis and Forecast 2016 – 2022

Source

Previous Posts

Male Androgenetic Alopecia

Male Androgenetic Alopecia

Follica Announces Progression to Pivotal Study Following Positive Interim Data in Male Androgenetic Alopecia

Follica, a clinical-stage biotech developing a regenerative platform for hair growth, today announced positive interim data from an ongoing safety and optimization study to treat hair loss in male androgenetic alopecia. In addition to being well tolerated and informing key treatment parameters, analysis of 20 male study participants with androgenetic alopecia showed that Follica’s approach achieved a visible and statistically significant improvement in non-vellus (visible) hair count after three months of treatment, compared to baseline.

Additionally, blinded head-to-head bench testing of the proprietary Follica device has shown significant therapeutic advantages in scalp treatment versus commercially available skin disruption devices. A pivotal study is expected to initiate at the end of 2019 subject to continued safety and efficacy in the optimization study.

Follica’s platform is designed to induce an “embryonic window” in adult skin via a proprietary form of micro-abrasion that initiates hair follicle neogenesis, the formation of new hair follicles from epithelial (skin) stem cells. This process of hair follicle neogenesis is enhanced through the application of a topical compound as part of the treatment regimen. In addition to the ongoing safety and optimization study, Follica has proof-of-concept data from prior clinical studies using prototype devices with different treatment parameters and therapeutic compounds. Follica’s translational work builds on an important basic discovery by George Cotsarelis, MD, Chair of the Department of Dermatology at the University of Pennsylvania, and a co-founder of Follica.

“Follica’s pioneering work in new hair formation has the potential to address a tremendous need,” said Ken Washenik, MD, Ph.D., president of Bosley Medical Group, clinical faculty of Dermatology at NYU school of medicine, and senior medical advisor to Follica. “The unique mechanism of action has been studied extensively and is truly differentiated from existing treatment options. The results I’ve reviewed in the interim analysis are exciting and very strong, and I look forward to the initiation of the pivotal study later this year.”

“Some of my past life was spent trying to stop hair from growing, but I’m equally enthusiastic to have been involved in helping advance and optimize George’s key discovery that shows promise for creating new hair,” said R. Rox Anderson, MD, PhD, professor of dermatology at Harvard Medical School, director of the Massachusetts General Hospital Laser Center, and scientific advisor to Follica, who conceived and developed many of the non-scarring treatments now widely used in medical and aesthetic care. These include laser treatments for birthmarks, microvascular and pigmented lesions, tattoo and permanent hair removal, as well as cryolipolysis (Coolsculpting®).

“The biology of wounding in humans is very complex, and our ability to translate its effects into new hair growth is sensitive to a range of treatment factors,” said Jason Bhardwaj, chief executive officer of Follica. “From years of clinical testing, we have optimized the dosing, frequency, and several other important parameters and translated these learnings into a unique and proprietary treatment. Based on this interim analysis and the results of three previously conducted studies, we are excited to move forward into a pivotal study at the end of 2019.”

The safety and optimization study is an endpoint-blinded, randomized, controlled study designed to evaluate Follica’s proprietary skin disruption device in men with androgenetic alopecia and to establish therapeutic parameters, including the optimal duration and frequency of treatment. The study will continue to enroll up to 60 men, ages 18-40, with moderate grades of androgenetic alopecia (Hamilton Norwood III-IV).

About Follica

Follica is a clinical-stage biotech developing a regenerative platform for hair growth. Founded by PureTech Health (PRTC.L), a co-inventor of the current platform and a group of world-renowned experts in hair follicle biology and regenerative medicine, Follica’s device platform has been shown to stimulate the development of new hair follicles and hair in three previously conducted clinical studies.

The company’s proprietary device is designed to induce an embryonic window via a device with optimized parameters to create micro-abrasions and initiate hair follicle neogenesis, the formation of new hair follicles from epithelial (skin) stem cells. This process is enhanced through the application of a topical compound. Follica is conducting an ongoing optimization trial, with a pivotal study in androgenetic alopecia expected to begin at the end of Q4 2019. Follica’s technology and strong IP is based on work exclusively licensed from the University of Pennsylvania that has been further enhanced and protected by Follica’s internal development work.

Follica Announces Progression to Pivotal Study Following Positive Interim Data in Male Androgenetic Alopecia

Source

Previous Posts

Global Alopecia Treatment Market

Global Alopecia Treatment Market

Global Alopecia Treatment Market– Industry Trends and Forecast to 2026

The Global Alopecia Treatment (Hair Loss) Market is expected to rise from its initial estimated value of USD 8.21 billion in 2018 to an estimated value of USD 12.40 billion by 2026 registering a CAGR of 5.3% in the forecast period of 2019-2026. This rise in the market can be attributed to the rising geriatric population along with high demand for surgical hair transplant and changing lifestyle.
Market Definition: Global Alopecia Treatment (Hair Loss) Market

Alopecia areata is a medical condition which is a type of alopecia which attacks the hair follicles causes the breakage or fall of hair leading to complete baldness. The patient suffering from alopecia areata, their scalp becomes patchy, diffused and confluent pattern leading the hair fall initially and later spread over the entire scalp termed as alopecia totalis or entire epidermis.

Alopecia areata is an autoimmune hair loss on the scalp or on the body and commonly it shows in the form of solitary and multiple patches of alopecia.

Market Drivers:

Rising geriatric population along with high demand for surgical hair transplant will boost the market
Changing lifestyle along with increase in stress level among working class population can fuel the growth of the market

Market Restraints:

High cost of alopecia treatment (hair loss) is acting as a major restraint for the market
Side effects/allergic reactions by treatment also acting as a major market restraint.

Segmentation: Global Alopecia Treatment (Hair Loss) Market

By Disease Type
Androgenic Alopecia
Alopecia Areata
Ciatricial Alopecia
Traction Alopecia
Alopecia Totalis
By Drug Type
Minoxidil
Finasteride
Cyclosporine
Others
By Gender
Male
Female
By Route of Administration
Oral
Topical
Injectable
By Distribution Channel
Hospital
Retail Pharmacies
Online Pharmacies
By Geography
North America
US
Canada
Mexico
South America
Brazil
Argentina
Rest of South America
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Turkey
Belgium
Netherlands
Switzerland
Rest of Europe
Asia-Pacific
Japan
China
South Korea
India
Australia
Singapore
Malaysia
Indonesia
Thailand
Philippines
Rest of Asia-Pacific
The Middle East and Africa
South Africa
Egypt
Saudi Arabia
United Arab Emirates
Israel
Rest of the Middle East and Africa

Key Developments in the Market:

In January, 2018, Concert Pharmaceuticals, Inc. announced U.S. FDA granted Fast Track designation for CTP-543, a novel, oral Janus kinase (JAK) inhibitor for the treatment of moderate-to-severe alopecia areata, a disease which attacks the hair follicles, leading to hair loss.
In May 2018, Histogen, Inc (U.S.) announced that received approval to Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) to study its lead product in female diffuse hair loss.
In March 2017, Perrigo Perrigo Company PLC (U.S.) announced the launch of over-the-counter Women’s Rogaine, which helps to regrow hair on top of the scalp.

Competitive Analysis: Global Alopecia Treatment (Hair Loss) Market

The global alopecia treatment (hair loss) market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of alopecia treatment (hair loss) market for global, Europe, North America, Asia Pacific, South America and Middle East & Africa.
Key Market Competitors: Global Alopecia Treatment (Hair Loss) Market

Few of the major market competitors currently working in the alopecia treatment (hair loss) market are Cipla, Viviscal, Dr. Reddy’s Laboratories Ltd., Regaine, Merck & Co., Inc, Ranbaxy Laboratories Ltd, Phyto – Alès Groupe, Kirkland Signature, Vitabiotics, Nanogen, Alpecin – Dr. Kurt Wolff GmbH & Co. KG, Rogaine – Johnson and Johnson, Histogen, Inc., Aclaris Therapeutics, Inc., Concert Pharmaceuticals, Inc., HCell Inc., GlaxoSmithKline plc., Perrigo Company PLC. and Daiichi Sankyo, Inc.
Research Methodology: Global Alopecia Treatment (Hair Loss) Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more please Request an Analyst Call or can drop down your inquiry.

The key research methodology used by DBMR Research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Primary Respondents:

Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.

Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Reasons to Purchase this Report:

Current and future of global alopecia treatment (hair loss) market outlook in the developed and emerging markets
The segment that is expected to dominate the market as well as the segment which holds the highest CAGR in the forecast period
Regions/Countries that are expected to witness the fastest growth rates during the forecast period
The latest developments, market shares, and strategies that are employed by the major market players

Customization of the Report:

All segmentation provided above in this report is represented at the country level
All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)

 

Global Alopecia Treatment Market– Industry Trends and Forecast to 2026

Source

Previous Posts

Concert Pharmaceuticals Presents Interim CTP-543 Phase 2 Data in Alopecia Areata

Concert Pharmaceuticals Presents Interim CTP-543 Phase 2 Data in Alopecia Areata

Concert Pharmaceuticals Presents Interim CTP-543 Phase 2 Data in Alopecia Areata during Late-Breaker Session at American Academy of Dermatology Annual Meeting

Interim Data Analysis from 8 mg Twice-Daily Cohort of Investigational CTP-543 Showed Statistically Significant Effect on Primary Endpoint in Patients with Moderate-to-Severe Alopecia Areata

Concert Pharmaceuticals, Inc. today announced that interim results from its Phase 2 clinical trial evaluating its product candidate CTP-543 in patients with moderate-to-severe alopecia areata will be presented in an oral presentation during the late-breaking clinical trials session at the American Academy of Dermatology (AAD) Annual Meeting on March 2, 2019, in Washington, DC.

The interim results from this dose-ranging trial showed that treatment with CTP-543 administered at an 8 mg twice-daily dose for 24 weeks met the primary endpoint with a statistically significant greater hair regrowth responder rate compared to placebo. The primary endpoint measures the proportion of patients who are responders to treatment, defined as a ≥ 50% relative reduction in their overall Severity of Alopecia Tool (SALT) score from baseline.

“Alopecia areata is a chronic autoimmune disease resulting in patchy or complete hair loss that can have a profound effect on patients’ health and well-being and can impact their daily lives. I am happy to see new investigational medicines emerging with promising clinical data, including Janus kinase (JAK) inhibitors such as CTP-543,” said Dr. Brett King, Associate Professor of Dermatology at Yale School of Medicine. “The data for CTP-543 shows that JAK inhibitors have the potential to be an effective treatment option for patients with this challenging disease.”

Patients with moderate-to-severe alopecia areata enrolled in the first two cohorts received 4 mg or 8 mg of CTP-543 twice-daily or placebo twice-daily for 24 weeks. The final cohort evaluating 12 mg of CTP-543 or placebo twice-daily is ongoing. The trial randomized 104 patients in the 4 mg and 8 mg cohorts.

The oral presentation will highlight the interim results for the 8 mg twice-daily dosing cohort of CTP-543, which achieved the Phase 2 trial’s primary endpoint, in patients with moderate-to-severe alopecia areata after 24 weeks of dosing. 47% of patients treated with 8 mg of CTP-543 twice-daily achieved a ≥ 50% relative reduction in their overall SALT, score from baseline, which was a significant improvement compared to 8.6% for placebo (p < 0.001).

The responders in the 8 mg twice-daily dose group were evenly distributed among patients with patchy alopecia areata and the more severe forms, alopecia totalis and alopecia universalis. The percentage of patients achieving the primary endpoint continued to increase up to Week 24, and regrowth of hair did not appear to plateau at Week 24. For the 4 mg cohort, 21% of patients achieved a ≥ 50% relative reduction in their overall SALT score from baseline, however these differences were not significantly different from placebo.

The most common side effects in the interim analysis were headache, upper respiratory tract infection, cough, acne and nausea. No serious adverse events were reported.

“We are very pleased that we were selected to present our initial safety and efficacy data with CTP-543 in patients with moderate to severe alopecia areata to the members of the Academy. We believe the results are highly encouraging and we are excited to share these data with the broader treatment community at the annual meeting,” stated James V. Cassella, Ph.D., Concert’s Chief Development Officer, who will make the oral presentation at AAD. “We look forward to advancing the development of CTP-543, as we continue our efforts to bring a new treatment to patients with this medical disease that currently has no approved medications.”

Details from the oral presentation, entitled “JAK Inhibitor CTP-543 Achieves Primary Endpoint in Phase 2a Trial in Alopecia Areata,” will be posted in the Scientific Presentations section of Concert’s website at the start of the oral presentation at the AAD on Saturday, March 2, 2019 at 1:20 p.m. ET.

The Phase 2 trial is a double-blind, randomized, placebo-controlled, sequential dose trial to evaluate the safety and efficacy of CTP-543 in adult patients with moderate-to-severe alopecia areata.

The primary outcome measure will utilize the Severity of Alopecia Tool (SALT) after 24 weeks of dosing. Patients were sequentially randomized to receive one of three doses of CTP-543 (4 mg, 8 mg, or 12 mg) or placebo twice-daily.

The final cohort evaluating a 12 mg twice-daily dose of CTP-543 compared to placebo is fully enrolled and topline data for the overall study, including the 12mg cohort, is expected in the third quarter of 2019. Additional information about the trial (NCT03137381) is available on www.clinicaltrials.gov.

About CTP-543
CTP-543 was discovered by applying Concert’s deuterium chemistry technology to modify ruxolitinib, a drug which inhibits Janus kinases 1 and 2 (JAK1 and JAK2) and is commercially available under the name Jakafi® in the United States for the treatment of certain blood disorders. Deuterium modification of ruxolitinib was found to alter its human pharmacokinetics in ways which may enhance its use as a treatment for alopecia areata. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for CTP-543.

About Alopecia Areata
Alopecia areata is an autoimmune disease that results in partial or complete loss of hair on the scalp and body that may affect up to 650,000 Americans at any given time1. The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp. Onset of the disease can occur throughout life with the majority of patients initially having symptoms by age 40. It is believed to equally affect both women and men. Alopecia areata can be associated with serious psychological consequences, including anxiety and depression. There are currently no drugs approved by the FDA for the treatment of alopecia areata.

Following the FDA’s Patient-Focused Drug Development meeting held in September 2017 on alopecia areata, the FDA summarized the input shared by patients and patient representatives in a Voice of the Patient report. Additional information on the PFDDI is available online.

About Concert
Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to treat serious diseases and address unmet patient needs. The Company’s approach starts with previously studied compounds, including approved drugs, in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert’s pipeline of innovative medicines targets autoimmune diseases and central nervous systems (CNS) disorders. For more information please visit www.concertpharma.com or follow us on Twitter at @ConcertPharma or on LinkedIn.

1 Fricke M. Epidemiology and Burden of alopecia areata: a systemic review. Clinical, Cosmetic and Investigational Dermatology. 2015; Vol 8. 397-403.

Concert Pharmaceuticals Presents Interim CTP-543 Phase 2 Data in Alopecia Areata

Source

Previous Posts

Treatment of alopecia universalis

Treatment of alopecia universalis

Treatment of alopecia universalis with topical Janus kinase inhibitors – a double-blind, placebo, and active-controlled pilot study

Background

Oral Janus kinase (JAK) inhibitors are currently being investigated in phase II and phase III clinical trials for several inflammatory skin diseases including alopecia areata (AA). Topical JAK inhibitors have been investigated in atopic dermatitis, psoriasis, and AA. While a number of case series using topical JAK inhibitors in AA have been published, to date there have been no randomized controlled clinical trials.

Methods

We conducted a phase I, 28-week prospective, placebo‐controlled, double‐blind study in patients with alopecia universalis investigating hair regrowth with two topical JAK inhibitors, 2% tofacitinib and 1% ruxolitinib. Topical clobetasol dipropionate 0.005% was the active comparator while vehicle was used as the placebo control. Sixteen patients were recruited for the study.

Results

Six patients demonstrated partial hair regrowth in areas treated with 2% tofacitinib ointment applied twice daily.

Five patients demonstrated partial hair regrowth in the areas treated with 1% ruxolitinib ointment.

Ten patients demonstrated partial hair regrowth in the areas treated with clobetasol dipropionate 0.05% ointment.

No regrowth was observed in the placebo-treated area. Interestingly, generalized hair regrowth was observed in two patients.

One patient had 100% regrowth over his entire scalp and eyebrows by week 24 but relapsed after 12 weeks.

A second patient also experienced generalized scalp regrowth and significant eyebrow growth and continued to maintain growth 14 weeks later.

Conclusion

Our findings suggest that topical JAK inhibitors could be developed as a potential new treatment for AA and alternative to clobetasol dipropionate 0.05% ointment.

Treatment of alopecia universalis with topical Janus kinase inhibitors – a double-blind, placebo, and active-controlled pilot study

Source

Previous Posts

Global Alopecia Market Insights, Forecast to 2025

Global Alopecia Market Insights, Forecast to 2025

Global Alopecia Market Insights, Forecast to 2025

Global Alopecia (Hair Loss Treatment) market is anticipated to grow at a CAGR of XX% by 2023, according to a new report published by ResearchVector Inc.

The report segments the market and forecasts its size, by volume and value, on the basis of application, by-products, and by geography (North America, Europe, Asia-Pacific, MEA and South America).

The Global Market for Alopecia (Hair Loss Treatment) to 2023 offers detailed coverage of guanidine Alopecia (Hair Loss Treatment) industry and presents main market trends. The market research gives historical and forecast market size, demand, and production forecasts, end use demand details, price trends, and company shares of the leading Alopecia (Hair Loss Treatment) producers to provide exhaustive coverage of the guanidine carbonate.

This research report includes the following contents:

  • Alopecia (Hair Loss Treatment) Product details, including pictures and technical specifications
  • Alopecia (Hair Loss Treatment) manufacturers, distributors and channels
  • Major players present in the Alopecia (Hair Loss Treatment)
  • Information on competitor market shares, revenue, unit sales etc
  • Breakdown by applications for the Market
  • Value chain and distributor details in the market

Key vendors:

  • Shiseido
  • Rohto
  • Unilever
  • Taisho
  • Angfa
  • LOreal
  • Kaminomoto
  • Merck
  • Yanagiya Honten
  • Amorepacific
  • Procter & Gamble
  • Himalaya
  • Gerolymatos International
  • Merz Pharma
  • Leader Teck
  • Vasu Healthcare
  • VLCC
  • Ales Group
  • Shanxi Ante
  • Wansheng Pharmaceutical
  • Advanced Skin and Hair
  • Humanwell Healthcare
  • Topfond
  • Lifes2good
  • Bawang
  • YNK Pharmaceutical
  • Apollo
  • Jingxiutang
  • Rogaine
  • Marico

Key regions:

United States, Canada, Mexico, China, India, Japan, South Korea, Australia, Indonesia, Singapore, Malaysia, Philippines, Thailand, Vietnam, Germany, France, UK, Italy, Spain, Russia, Brazil, Rest of Central & South America, GCC Countries, Turkey, Egypt, South Africa

Additionally, the market is segmented by the following sectors

  • Shampoos and Conditioners
  • Medicine Product

Not only this, but figures covering the end-user applications are also provided according to the following classification

  • Men
  • Women

In summary, the report serves to study and analyse the Alopecia (Hair Loss Treatment) size (value & volume) by the company, key regions/countries, products and application, history data from 2013 to 2017, and forecast to 2025. This report includes the estimation of market size for value (million US$) and volume (K MT).

Both top-down and bottom-up approaches have been used to estimate and validate the market size of Alopecia (Hair Loss Treatment), to estimate the size of various other dependent submarkets in the overall market.

Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares split, and breakdowns have been determined using secondary sources and verified primary sources.

Overall the report is an excellent source for managers, researches and top executives alike to analyse and get clarity on the market standings and business forecast. We provide the information after thorough research and analysis saving precious hours and budget for the companies. We have been serving major clients like Sony, BCG, PWC, Mck, Hewlett Packard, Technicolor Etc.

Number of Pages 148

Published Date12 September 2018

Single User Price $3900.0

Enterprise User Price$7800.0

Global Alopecia Market Insights, Forecast to 2025

Source